key: cord-294854-rvrgcugn authors: Hu, Biying; Huang, Shaoying; Yin, Lianghong title: The cytokine storm and COVID‐19 date: 2020-06-27 journal: J Med Virol DOI: 10.1002/jmv.26232 sha: doc_id: 294854 cord_uid: rvrgcugn Coronavirus disease 2019 (COVID‐19), which began in Wuhan, China in December 2019 has caused a large global pandemic and poses a serious threat to public health. More than four million cases of COVID‐19, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), have been confirmed as of May 11, 2020. SARS‐CoV‐2 is a highly pathogenic and transmissible coronavirus that primarily spreads through respiratory droplets and close contact. A growing body of clinical data suggests that a cytokine storm is associated with COVID‐19 severity and is also a crucial cause of death from COVID‐19. In the absence of antivirals and vaccines for COVID‐19, there is an urgent need to understand the cytokine storm in COVID‐19. Here, we have reviewed the current understanding of the features of SARS‐CoV‐2 and the pathological features, pathophysiological mechanisms, and treatments of the cytokine storm induced by COVID‐19. Additionally, we suggest that the identification and treatment of the cytokine storm are important components for rescuing patients with severe COVID‐19. This article is protected by copyright. All rights reserved. An outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread throughout the world 1 . The initial symptoms of COVID-19 mainly include fever, cough, myalgia, fatigue, or dyspnea. In the later stages of the disease, dyspnea may occur and gradually develop into acute respiratory distress syndrome (ARDS) or multiple organ failure (MOF) 2 . It has been reported that a cytokine storm is Accepted Article associated with the deterioration of many infectious diseases, including severe acute respiratory syndrome (SARS) 3 and Middle East respiratory syndrome (MERS) 4 . The cytokine storm caused by has been suggested to be associated with COVID-19 severity 2, 5 . However, there is currently a limited understanding of the cytokine storm in severe COVID-19. Therefore, here, we have discussed the current findings and treatment strategies for the cytokine storm in severe COVID-19. SARS-CoV-2 is the newest coronavirus known to infect humans. SARS-CoV, MERS-CoV, and SARS-CoV-2 cause severe pneumonia, while other human coronaviruses, including 229E, OC43, HKU1, and NL63, cause only the common cold 6 . SARS-CoV-2 belongs to the genus Betacoronavirus, which also includes SARS-CoV and MERS-CoV, both of which have caused SARS and MERS, respectively 7 . SARS-CoV-2, SARS-CoV, and MERS-CoV have similarities and differences. Genetic sequence analysis has revealed that SARS-CoV-2 shares 79% sequence identity with SARS-CoV and 50% identity with MERS-CoV 8 . The genomes of SARS-CoV-2 and the bat coronavirus RaTG13 are 96.2% homologous 9 . As of May 11, 2020, COVID-19 has resulted in 278,892 deaths and 4,006,257 cases, with an approximate case fatality rate of 7.0% 10 . SARS-CoV and MERS-CoV had a case fatality rate of 9.6% (774/8,096) and 34.4% (858/2,494), respectively 11 . The reproduction number (R0) of COVID-19 is thought to be This article is protected by copyright. All rights reserved. Accepted Article between 2 and 2.5 12 , which is slightly higher than of SARS (1.7.1.9) and MERS (<1) 13 . COVID-19 appears to be more infectious than SARS and MERS, but may be less severe. The origins of SARS-CoV, MERS-CoV, and SARS-CoV-2 are considered to be zoonotic. Both SARS-CoV and MERS-CoV originated in bats and spread directly to humans from marked palm civets and dromedary camels, respectively 14 . However, the origin of SARS-CoV-2 remains unclear. SARS-CoV-2 has been reported to be transmitted between humans through direct contact, aerosol droplets, the fecal-oral route, and intermediate viruses from symptomatic and asymptomatic patients 15 . SARS-CoV and MERS-CoV are also thought to spread from infected to non-infected individuals through direct or indirect contact 15 19 proposed that SARS-CoV-2 infection triggers an excessive immune response known as a cytokine storm in cases of severe COVID-19. A cytokine storm is a potentially fatal immune disease characterized by the high-level activation of immune cells and excessive production of massive inflammatory cytokines and chemical mediators 20 . It is considered to be the main cause of disease severity and death in Accepted Article COVID-19 patients 5 , and is related to high levels of circulating cytokines, severe lymphopenia, thrombosis, and massive mononuclear cell infiltration in multiple organs 21 . It has been found that SARS-CoV-2 genomes from different parts of the world have evolved in different clusters 22, 23 . Forster et al. 23 reported there to be at least three central variants of SARS-CoV-2 globally, named A, B, and C. The A type is the most similar to the bat coronavirus and is mainly found in the United States and Australia. The B type is more common in East Asia and has evolved through several mutations. The C type is primarily found in Europe. Different viral isolates exhibit significant differences in pathogenicity and viral load 24 . Notably, given the diverse clinical symptoms of patients, it will be challenging to establish a genotype-phenotype relationship. With new sequences being uploaded to the GIASID (Global initiative on sharing all influenza data) every day, new results may be produced as more data become available. The emergence of variants may add to the challenges of vaccine development. Pathological alterations in COVID-19 patients include pulmonary edema, diffuse alveolar injury with the formation of hyaline membranes, the presence of reactive type II pneumocyte hyperplasia, proteinaceous aggregates, fibrinous Accepted Article exudates, monocytes and macrophages within alveolar spaces, and inflammatory infiltration of interstitial mononuclear cells [25] [26] [27] [28] . Electron microscopy has revealed the presence of SARS-CoV-2 virus particles in bronchial and alveolar type II epithelial cells, but not in other tissues 26, 27 . Therefore, although a PCR test may be negative from blood or throat swabs, SARS-CoV-2 viral inclusions may be detected in the lungs. Immunohistochemical staining indicated that CD68 + macrophages, CD20 + B cells, and CD8 + T cells infiltrated the alveolar cavity and alveoli 26 . The levels of CD8 ＋ T cells may be slightly higher than that of CD4 ＋ T cells within the alveolar septa 29 Cellular entry of SARS-CoV-2 depends on the binding of S proteins covering the surface of the virion to the cellular ACE2 receptor 9, 33 and on S protein This article is protected by copyright. All rights reserved. priming by TMPRSS2, a host membrane serine protease 33 Table 1 , and cytokine secretion patterns based on COVID-19 severity are shown in Table 2 . Prevention and mitigation of the cytokine storm may be the crux to saving patients with severe COVID-19. Currently, many therapies are being evaluated in clinical trials due to a lack of high-quality evidence. Corticosteroids inhibit the host inflammatory response and suppress the immune response and pathogen clearance 46 Overall, although evidence indicates a potential role for the use of corticosteroids This article is protected by copyright. All rights reserved. in patients with severe COVID-19, caution should be exercised given the possibilities of viral rebound and adverse events. Given their in vitro antiviral effects and anti-inflammatory properties, CQ and its analog HCQ are considered to be potential therapies for COVID-19. Considering the severe side effects of CQ, HCQ may be a better therapeutic option. CQ and HCQ are able to reduce CD154 expression in T cells 52 However, the risks associated with TCZ (e.g., severe infections, thrombocytopenia, neutropenia, liver damage) should also be noted 64 . It is unclear whether there are different effects between IL-6 antagonists (siltuximab) and IL-6R antagonists (TCZ). Siltuximab binds to sIL-6 and inhibits only cis and trans signaling. TCZ binds to both mIL-6R and sIL-6R and inhibits both cis and trans signaling and trans presentation 40, 65 . Of note, IL-6 inhibitors are not able to bind to IL-6 produced by viruses such as HIV and human herpesvirus-8 65 . Currently, the application of TCZ for COVID-19 treatment is under study. The three drugs mentioned above (corticosteroids, HCQ, TCZ) are immunosuppressants. Owing to overall damage to the immune system caused by autoimmune diseases and the iatrogenic effects of immunosuppressants, the risk of infection in patients with autoimmune diseases will be increased compared to the general population. Currently, rheumatology societies 66-69 recommend the use of immunosuppressive drugs (except glucocorticoids) to be suspended in COVID-19 patients. MSCs have a wide range of immune regulatory functions and can inhibit the abnormal activation of T lymphocytes and macrophages and the secretion of pro-inflammatory cytokines 70 . MSC therapy was found to significantly reduce the mortality of patients with H7N9-induced ARDS and had no harmful side effects 71 . A clinical trial of MSC therapy revealed that MSCs were able to rapidly and significantly improve the clinical symptoms of COVID-19 without any observed adverse effects 72 . Although side effects of MSC treatment are rarely reported, the safety and effectiveness of this treatment require further investigation. Anakinra, an IL-1 receptor antagonist that blocks the activity of pro-inflammatory cytokines IL-1α and IL-1β, has been reported to improve respiratory function and increase the survival rate of COVID-19 patients 73 . IL-1 receptor antagonists increase the risk of bacterial infections, but this is extremely rare for anakinra 65 . Janus kinase (JAK) inhibitors can inhibit inflammatory cytokines and reduce the ability of viruses to infect cells 74 Table 3 . The cytokine storm leads to deleterious clinical manifestations or even acute mortality in critically ill patients with COVD-19. Impaired acquired immune This article is protected by copyright. All rights reserved. responses and uncontrolled inflammatory innate responses may be associated with the mechanism of the cytokine storm in COVID-19. Early control of the cytokine storm through therapies such as immunomodulators and cytokine antagonists is essential to improve the survival rate of COVID-19 patients. Although many research articles are published each month, majority of the existing literature about COVID-19 comes from descriptive works. Additionally, high-quality evidence will be necessary to understand and treat the cytokine storm of COVID-19. Potential for global spread of a novel coronavirus from China Clinical features of patients infected with 2019 novel coronavirus in Wuhan An interferon-gamma-related cytokine storm in SARS patients Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis COVID-19: consider cytokine storm syndromes and immunosuppression Chapter Eight -Hosts and Sources of Endemic Human Coronaviruses Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding A pneumonia outbreak associated with a new coronavirus of probable bat origin World Health Organization W. Coronavirus disease (COVID-19)Situation Report -112 Genetic Recombination, and Pathogenesis of Coronaviruses Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19) 2020 COVID-19, SARS and MERS: are they closely related? Origin and evolution of pathogenic coronaviruses The COVID-19 Pandemic: A Comprehensive Review of Coronaviruses -drug discovery and therapeutic options Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Clinical Characteristics of Coronavirus Disease 2019 in China COVID-19 with Different Severity: A Multi-center Study of Clinical Features Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity Phylogenetic network analysis of SARS-CoV-2 genomes Patient-derived mutations impact pathogenicity of SARS-CoV-2 Pathological findings of COVID-19 associated with acute respiratory distress syndrome Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient SARS-CoV-2 and viral sepsis: observations and hypotheses Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19 Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 The clinical pathology of severe acute respiratory syndrome (SARS): a report from Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus Neutrophil extracellular traps in COVID-19. JCI insight COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome Understanding Angiotensin II Type 1 Receptor Signaling in Vascular Pathophysiology. Hypertension (Dallas, Tex: 1979) Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines Cytokine release syndrome in severe COVID-19 Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile Clinical and immunological features of severe and moderate coronavirus disease 2019 Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients A Dynamic Immune Response Shapes COVID-19 Cell host & microbe COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience On the use of corticosteroids for 2019-nCoV pneumonia Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. The Journal of infection Hydroxychloroquine inhibits CD154 expression in CD4 T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling Effects of chloroquine on viral infections: an old drug against today's diseases? In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of Accepted Article coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study) Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality Chinese Clinical Trail Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia Effective treatment of severe COVID-19 patients with tocilizumab Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response BSR guidance for patients during Covid-19 outbreak ACR guidance for patients during Covid-19 outbreak 2020 Australian Rheumatology Association guidance for patients during Covid-19 outbreak 2020 The immunomodulatory function of mesenchymal stem cells: mode of action and pathways Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome,and hyperinflammation: a retrospective cohort study Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. The Journal of infection Baricitinib as potential treatment for 2019-nCoV acute respiratory disease The cytokine storm of severe influenza and development of immunomodulatory therapy Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection We thank all the doctors and nurses who have bravely fought the virus during the COVID-19 pandemic. The authors declare no conflicts of interest. 1